Humacyte (HUMA) Accumulated Depreciation (2020 - 2025)

Humacyte (HUMA) has reported Accumulated Depreciation for 4 consecutive years, with $41.3 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Accumulated Depreciation rose 14.53% year-over-year to $41.3 million in Q4 2025; TTM through Dec 2025 was $41.3 million, a 14.53% increase from a year earlier, with the FY2025 full-year figure at $41.3 million, up 14.53% from the prior year.
• Accumulated Depreciation was $41.3 million for Q4 2025 at Humacyte, up from $36.1 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $41.3 million in Q4 2025 and troughed at $18.9 million in Q3 2021.
• A 3-year average of $32.1 million and a median of $36.1 million in 2024 frame the typical range for Accumulated Depreciation.
• The widest YoY moves for Accumulated Depreciation: up 14.53% in 2025, down 14.53% in 2025.
• Over 3 years, Accumulated Depreciation stood at $18.9 million in 2021, then soared by 90.83% to $36.1 million in 2024, then advanced by 14.53% to $41.3 million in 2025.
• The last three Accumulated Depreciation figures came in at $41.3 million (Q4 2025), $36.1 million (Q4 2024), and $18.9 million (Q3 2021), per Business Quant data.